We have substantial experience in performing studies with targeted radionuclide therapy in oncology. Our capabilities include testing of alpha- as well as beta-emitting ligands in subcutaneous, orthotopic or metastatic cancer models.
We facilitate clinical translation into Phase I studies including clinical trial design and execution in collaboration with our clinical partners.
Approval of handling alpha- and beta-emitters, e.g. 177Lu, 131I, 227Th
Targeted radionuclide therapy in subcutaneous and orthotopic PDX models
Targeted radionuclide therapy in metastatic models
Custom radiolabeling of small molecules, peptides, proteins and antibodies